Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21)

The summary for the Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21): This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse, National Institutes of Health, encourages Exploratory / Developmental Research Project Grant (R21) applications from institutions/ organizations that propose to develop non-invasive (including but not limited to urine, sweat or oral fluids) or minimally invasive (such as fingerstick), methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs). The announcement has two main aims. The first aim is to encourage the development of devices / techniques that will improve estimations of a subjects consumption of an abused drug (i.e. both quantity and frequency of consumption) during an outpatient clinical trial. Such a system would allow the objective assessment of whether a medication reduces drug abuse, even if abstinence is not achieved. Proposed solutions should be able to assess systemic drug levels and be safe, portable, affordable and simple enough for subjects to take multiple samples at home and return them to the clinic for batch analysis.
Federal Grant Title: Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-12-238
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: Sep 07, 2015
Original Application Deadline: Sep 07, 2015
Posted Date: Jul 16, 2012
Creation Date: Jul 16, 2012
Archive Date: Oct 08, 2015
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020 FederalGrants.com